Budesonide Commercial Medicine Market 2023 Some Basic Influencing Factors Making Its Booming Industry Astr - openPR
| 4114 Stock | TWD 34.20 0.15 0.44% |
Slightly above 53% of Synmosa Biopharma's investor base is interested to short. The analysis of current outlook of investing in Synmosa Biopharma suggests that many traders are impartial regarding Synmosa Biopharma's prospects. Synmosa Biopharma's investing sentiment can be driven by a variety of factors including economic data, Synmosa Biopharma's earnings reports, geopolitical events, and overall market trends.
Synmosa Biopharma stock news, alerts, and headlines are usually related to its technical, predictive, social, and fundamental indicators. It can reflect on the current distribution of Synmosa daily returns and investor perception about the current price of Synmosa Biopharma as well as its diversification or hedging effects on your existing portfolios.
Synmosa |
Budesonide Commercial Medicine Market 2023 Some Basic Influencing Factors Making Its Booming Industry Astr openPR
Read at news.google.com
 |
Synmosa Biopharma Fundamental Analysis
We analyze Synmosa Biopharma's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Synmosa Biopharma using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Synmosa Biopharma based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Net Income
Net Income Comparative Analysis
Synmosa Biopharma is currently under evaluation in net income category among its peers. Net income is the profit of a company for the reporting period, which is derived after taking revenues and gains and subtracting all expenses and losses. Net income is one of the most-watched numbers by money managers as well as individual investors.
Synmosa Biopharma Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Synmosa Biopharma stock to make a market-neutral strategy. Peer analysis of Synmosa Biopharma could also be used in its relative valuation, which is a method of valuing Synmosa Biopharma by comparing valuation metrics with similar companies.
Peers
Synmosa Biopharma Related Equities
| 2379 | Realtek Semiconductor | 3.45 | ||||
| 6435 | Sinopower Semiconductor | 0.97 | ||||
| 3094 | Davicom Semiconductor | 0.38 | ||||
| 5425 | Taiwan Semiconductor | 0.64 | ||||
| 8462 | Power Wind | 0.74 | ||||
| 6770 | Powerchip Semiconductor | 0.96 | ||||
| 6708 | Mars Semiconductor | 1.01 |
Additional Tools for Synmosa Stock Analysis
When running Synmosa Biopharma's price analysis, check to measure Synmosa Biopharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Synmosa Biopharma is operating at the current time. Most of Synmosa Biopharma's value examination focuses on studying past and present price action to predict the probability of Synmosa Biopharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Synmosa Biopharma's price. Additionally, you may evaluate how the addition of Synmosa Biopharma to your portfolios can decrease your overall portfolio volatility.